Humalog Mix75 25 is intended only for subcutaneous administration. Humalog Mix75 25 should not be administered intravenously. Dosage regimens of Humalog Mix75 25 will vary among patients and should be determined by the Health Care Professional familiar with the patient's metabolic needs, eating habits, and other lifestyle variables. Humalog has been shown to be equipotent to regular human insulin on a molar basis. One unit of Humalog has the same glucose-lowering effect as one unit of regular human insulin, but its effect is more rapid and of shorter duration. Humalog Mix75 25 has a similar glucose-lowering effect as compared with Humulin 70 30 on unit for unit basis. The quicker glucose-lowering effect of Humalog is related to the more rapid absorption rate of insulin lispro from subcutaneous tissue. Humalog Mix75 25 starts lowering blood glucose more quickly than regular human insulin, allowing for convenient dosing immediately before a meal within 15 minutes ; . In contrast, mixtures containing regular human insulin should be given 30 to 60 minutes before a meal. The rate of insulin absorption and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables. As with all insulin preparations, the time The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic differences between insulin lispro and soluble human insulin, as measured during a glucose clamp procedure, were maintained over a wide range of renal function. Insulin lispro has been shown to be equipotent to human insulin on a molar basis but its effect is more rapid and of a shorter duration. In two 8-month open label crossover studies, type 2 diabetes patients who were either new to insulin therapy or already using one or two injections of insulin, received 4 months of treatment with Humalog Mix25 used twice daily with metformin ; and insulin glargine used once daily with metformin ; in a randomised sequence. Detailed information can be found in the following table. Insulin-Naive Patients n 78 0.63 U kg 1.30% mean at baseline 8.7% ; 3.46 mM Not Insulin-Naive Patients n 97 0.42 U kg 1.00 % mean at baseline 8.5% ; 2.48 mM.
In vulval carcinomas, only 3 of 11 27% ; had detectable high risk HPV DNA type 16, and 33; type 16, 18 and 33 ; . Therefore, there is a greater prevalence of HPV infection associated with VIN compared with that of vulval cancer P 0.014 ; . HLA Expression in Normal and Neoplastic Vulva. Monomorphic HLA class I expression was analyzed by staining with W6 32 anti- 2m. A limited number of allele-specific, monoclonal antibodies were used to analyze expression of HLA A and B loci, as indicated in "Materials and Methods, " providing information on appropriately genetically positive individuals indicated by labeling of the stromal tissue. Normal HLA class I expression was seen as homogeneous, with staining of both epithelial cells epidermis ; and stroma dermis ; giving a positive result. HLA class II expression in normal vulval skin was limited to the stroma, whereas the epithelium was negative data not shown ; . There were, however, Langerhans dendritic ; and immune infiltrating cells forming islands of class II positivity within vulval skin. Of the 11 vulval carcinomas studied, 9 showed total HLA class I down-regulation confirmed by allele locus-specific reagents in genetically positive cases. HLA class II expression was not up-regulated in these carcinomas. Two HLA class I positive tumors were associated with lichen sclerosis and were HPV negative. Three of the remaining carcinomas were found to be positive for high risk HPV Table 2 ; . Table 1 summarizes the HLA phenotypes of the 32 high-grade VIN lesions studied. Nine 28% ; of VIN biopsies showed HLA class I loss, of which 6 19% ; showed total and 3 of 32 9% ; allelic downregulation Table 2 and Figs. 2 and 3 ; . HLA expression was shown to be stable with no variation between pretreatment and posttreatment biopsies where this could be analyzed 19 cases ; . Interestingly, none of the 10 responding VIN patients showed any evidence of HLA class.